PTX-100

DRUG3 trials

Sponsors

Prescient Therapeutics Limited, Prescient Therapeutics, Ltd.

Conditions

Advanced CancerCTCLCutaneous T-Cell LymphomaPTCL

Phase 1

Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort

CompletedNCT03900442

Prescient Therapeutics, Ltd.Advanced Cancer, PTCL

Start: 2019-09-01End: 2025-08-08Updated: 2025-09-02

Phase 2

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

RecruitingNCT06854653

Prescient Therapeutics, Ltd.CTCL

Start: 2025-03-28End: 2028-06-01Target: 115Updated: 2026-09-09

An Open-Label, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PTX-100 Monotherapy in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma.

RecruitingCTIS2025-521852-45-00

Prescient Therapeutics LimitedCutaneous T-Cell Lymphoma

Start: 2026-01-22Target: 25Updated: 2026-01-22

Related Papers

Pharmacokinetic and Dose Response Relationships Observed in the Study “a Phase 1, Open- Label Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTX-100 in Patients with Advanced and Relapsed/Refractory T Cell Lymphoma”

Blood2024-11-051 citations

Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients with Advanced Malignancies

Blood2023-11-026 citations